IFNA2 and COVID-19: A reduction in viral load and clinical status improvement in moderate COVID-19 cases after subcutaneous administration of pegylated IFN-α2b was also reported in a phase II clinical trial and a phase III clinical trial [97,98], but no difference was observed for inflammatory biomarkers or in the duration of hospitalization.